SCHEMBL434451

SCHEMBL434451

COc1ccc(C(=O)Cc2c(Cl)cncc2Cl)c2c1OC1(CCCC1)O2

nearest known ligand 0.66

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.66
PDE4D Q08499 15/20 0.58
PDE4B Q07343 2/20 0.49
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
PDE4C Q08493 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6836821 0.99 PDE4A (0.65) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL5751710 0.99 PDE4A (0.65) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL14456335 0.94 PDE4A (0.59) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL4565777 0.92 PDE4A (0.78) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL3304195 0.92 PDE4A (0.77) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL3299351 0.91 PDE4A (0.62) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL3304549 0.91 PDE4A (0.62) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL13395949 0.89 PDE4A (0.60) PDE4APDE4DPDE4BPDE3BPDE3A
SCHEMBL6837875 0.89 PDE4D (0.63) PDE4APDE4DPDE4BPDE4C
SCHEMBL3305166 0.88 PDE4A (0.59) PDE4APDE4DPDE4BPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012051-A1 EXTERNAL PREPARATION KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-01-08 US claimed
US-20060239927-A1 Drug for airway administration KYOWA HAKKO KOGYO CO., (JP) 2006-10-26 US claimed
US-20060205749-A1 Remedy and/or preventive for lung diseases KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-14 US claimed
US-20060199789-A1 medical composition KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-07 US claimed
US-20060173028-A1 Therapeutic and/or preventive agent for chronic skin disease KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-08-03 US claimed
EP-1634606-A1 DRUG FOR AIRWAY ADMINISTRATION KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-15 EP claimed
EP-1621196-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CHRONIC SKIN DISEASE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-01 EP claimed
EP-1616569-A1 MEDICINAL COMPOSITION KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP claimed
EP-1609471-A1 REMEDY AND/OR PREVENTIVE FOR LUNG DISEASES KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-12-28 EP claimed
WO-2023203022-A1 TREATMENT OF NEUTROPHILIC DERMATOSES UNION therapeutics A/S (DK) 2023-10-26 WO disclosed
CN-108368094-B Non-steroidal glucocorticoid receptor modulators for topical drug delivery 利奥制药有限公司 2021-07-02 CN disclosed
US-10994082-B2 Inhaler counter ASTRAZENECA AB (SE) 2021-05-04 US disclosed
EP-3350175-B1 NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY LEO PHARMA AS (DK) 2019-11-06 EP disclosed
US-20190175849-A1 INHALER COUNTER BANG & OLUFSEN MEDICOM A/S (DK) 2019-06-13 US disclosed
WO-2004087147-A1 REMEDY AND/OR PREVENTIVE FOR LUNG DISEASES KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-10-14 WO disclosed
WO-2004082683-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CHRONIC SKIN DISEASE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-30 WO disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
EP-0771794-A1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 PDE4A 4879/4885PDE4D 4870/4885PDE4B 4877/4885
US-20060205749-A1 Remedy and/or preventive for lung diseases MPO, ELANE, MMP8 PDE4A 806/4885PDE4D 1967/4885PDE4B 1051/4885
US-20060199789-A1 medical composition NR3C2, CYP11B2, CYP11B1 PDE4A 149/4885PDE4D 503/4885PDE4B 152/4885
US-20060239927-A1 Drug for airway administration PDE12, PDE4A, PDE4B PDE4A 2/4885PDE4D 7/4885PDE4B 3/4885
US-20090012051-A1 EXTERNAL PREPARATION CYP4A11, CYP46A1, CYP11B2 PDE4A 406/4885PDE4D 514/4885PDE4B 423/4885
US-20060173028-A1 Therapeutic and/or preventive agent for chronic skin disease SERPINB1, CYP24A1, MMP8 PDE4A 616/4885PDE4D 951/4885PDE4B 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.